MRC1 — Mannose Receptor C Type 1

📖 Wiki Page

gene1715 wordssynced 2026-04-02

MRC1 — Mannose Receptor C Type 1 (CD206)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">MRC1 Gene (CD206)</th></tr>
<tr><td>Gene Symbol</td><td>MRC1</td></tr>
<tr><td>Full Name</td><td>Mannose Receptor C Type 1</td></tr>
<tr><td>Chromosomal Location</td><td>10p12.33</td></tr>
<tr><td>NCBI Gene ID</td><td>[4360](https://www.ncbi.nlm.nih.gov/gene/4360)</td></tr>
<tr><td>OMIM</td><td>[607075](https://omim.org/entry/607075)</td></tr>
<tr><td>Ensembl ID</td><td>[ENSG00000138739](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138739)</td></tr>
<tr><td>UniProt ID</td><td>[P22897](https://www.uniprot.org/uniprot/P22897)</td></tr>
<tr><td>Protein Length</td><td>1456 amino acids</td></tr>
<tr><td>Subcellular Location</td><td>Plasma membrane, endosomes</td></tr>
<tr><td>Associated Diseases</td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Multiple Sclerosis](/diseases/multiple-sclerosis), Neuroinflammation</td></tr>
</table>
</div>

Overview

...

MRC1 — Mannose Receptor C Type 1 (CD206)

Overview

Mermaid diagram (expand to render)

MRC1 (Mannose Receptor C Type 1), also known as CD206, encodes a C-type lectin receptor that plays a critical role in immune recognition and clearance of glycoproteins. Originally identified as a mannose-specific lectin, MRC1 is expressed primarily on macrophages, dendritic cells, and microglia, where it mediates endocytosis, phagocytosis, and immune regulation["@gandy2010"].

In the central nervous system, MRC1 serves as a hallmark of alternatively activated (M2-polarized) microglia and is implicated in the clearance of amyloid-beta (Abeta) plaques in Alzheimer's disease, the modulation of neuroinflammatory responses, and the maintenance of brain immune homeostasis["@velez2015"][@yang2019]. The receptor has also attracted significant interest as a biomarker for microglial activation and as a potential target for therapeutic interventions in neurodegenerative diseases.

Gene Structure and Evolution

Genomic Organization

The MRC1 gene is located on chromosome 10p12.33 and spans approximately 50 kb of genomic DNA. The gene consists of 30 exons that encode a type I transmembrane glycoprotein with a large extracellular domain containing multiple functional modules.

Evolutionary Conservation

MRC1 shows significant evolutionary conservation across mammals, birds, and amphibians, with the mannose-binding domain highly conserved.

Splice Variants

Multiple MRC1 splice variants have been identified including the canonical transmembrane receptor and soluble forms.

Protein Structure and Domains

Domain Architecture

MRC1 is a 175 kDa type I transmembrane glycoprotein with:

N-terminal cysteine-rich domain (CRD): Binds sulfated carbohydrates

Fibronectin type II (FNII) domain: Mediates collagen binding

Multiple C-type lectin domains (8-10): Carbohydrate recognition

Transmembrane domain: Single pass helix

Cytoplasmic tail: Contains endocytosis motifs

Expression and Cellular Distribution

Tissue Distribution

High expression in macrophages, dendritic cells, microglia, liver Kupffer cells, and lung alveolar macrophages. Moderate expression in spleen, kidney, and skin.

Brain Expression

In the CNS, MRC1 is expressed almost exclusively by microglia[@bauer1994], with higher expression in white matter and upregulated in neuroinflammation.

Biological Functions

Immune Recognition and Clearance

MRC1 functions as a pattern recognition receptor recognizing:

Pathogen-associated molecular patterns (mannose-rich glycans)
Endogenous ligands including Aβ peptides

Endocytosis and Phagocytosis

Mediates efficient endocytosis of glycoproteins, contributing to debris clearance, Aβ clearance, and tissue remodeling.

CNS-Specific Functions

In the brain, MRC1 on microglia mediates amyloid clearance, neuroinflammation modulation, tissue repair, and neuronal support.

Role in Neurodegenerative Diseases

Alzheimer's Disease

MRC1 serves as an M2 microglial marker and contributes to amyloid clearance. Impaired MRC1 function may contribute to plaque accumulation[@yang2019][@gutmann2020][@orlando2022].

Parkinson's Disease

MRC1 is involved in alpha-synuclein clearance and microglial activation in PD models.

Multiple Sclerosis

MRC1+ microglia are found in active demyelinating lesions, with roles in clearance of myelin debris and promotion of oligodendrocyte precursor differentiation.

Interaction Network

MRC1 interacts with TREM2 and CD36 in phagocytosis, LSP1 and moesin for signaling, and is regulated by IL-10 and TGF-β.

Microglial Polarization and MRC1

M2 Polarization Paradigm

MRC1 serves as a canonical marker for alternatively activated, M2-polarized microglia[@martinez2021][@ostuni2013]. This polarization state contrasts with the pro-inflammatory M1 phenotype associated with classical activation. The M2 state encompasses several functional subtypes:

M2a phenotype: Induced by IL-4 and IL-13, characterized by high MRC1 expression, involved in tissue repair and anti-inflammatory functions.

M2b phenotype: A mixed phenotype induced by immune complexes, showing both M1 and M2 markers.

M2c phenotype: Induced by IL-10 and TGF-β, associated with tissue remodeling and phagocytic activity.

Epigenetic Regulation of MRC1

The expression of MRC1 is dynamically regulated by epigenetic mechanisms including DNA methylation and histone modifications[@ostuni2013]. This regulation allows microglia to adapt their functional phenotype in response to environmental cues. Key epigenetic regulators include:

HDAC activity: Histone deacetylases modulate MRC1 expression
DNA methylation: Promoter methylation patterns correlate with MRC1 transcriptional activity
Chromatin accessibility: ATAC-seq studies reveal dynamic chromatin states at the MRC1 locus

Role in Neurodegenerative Diseases

Alzheimer's Disease

MRC1 serves as an M2 microglial marker and contributes to amyloid clearance. Impaired MRC1 function may contribute to plaque accumulation[@yang2019][@gutmann2020][@orlando2022].

Amyloid Clearance Mechanisms: MRC1 on microglia recognizes mannose-containing glycans on Aβ peptides, facilitating their binding and internalization. This receptor-mediated phagocytosis represents a significant pathway for Aβ clearance from the brain parenchyma.

MRC1+ Microglia in AD Brain: Immunohistochemical studies demonstrate increased numbers of MRC1+ (CD206+) microglia in AD brain tissue, particularly in proximity to amyloid plaques[@orlando2022]. The density of these cells correlates with local amyloid burden, suggesting a compensatory response to plaque deposition.

Therapeutic Enhancement: Strategies to enhance MRC1-mediated clearance include:

Agonists that promote M2 microglial polarization
Recombinant MRC1 ectodomain as a soluble therapeutic
Gene therapy approaches to increase MRC1 expression

Parkinson's Disease

MRC1 is involved in alpha-synuclein clearance and microglial activation in PD models.

Alpha-synuclein Recognition: MRC1 can recognize mannose-rich motifs on aggregated α-synuclein, facilitating its uptake and degradation. This clearance pathway may be impaired in PD, contributing to intracellular protein accumulation.

Neuroinflammation Modulation: MRC1+ microglia in PD brain exhibit both protective and pathogenic functions. While they can clear extracellular α-synuclein, they may also release pro-inflammatory cytokines that contribute to dopaminergic neuron loss.

Multiple Sclerosis

MRC1+ microglia are found in active demyelinating lesions, with roles in clearance of myelin debris and promotion of oligodendrocyte precursor differentiation[@zhang2021].

Myelin Debris Clearance: Efficient removal of degenerating myelin is essential for successful remyelination. MRC1-mediated phagocytosis contributes to this process by recognizing mannose-containing myelin glycoproteins.

OPC Differentiation: M2 microglia secretes growth factors that promote oligodendrocyte precursor cell (OPC) differentiation. This paracrine signaling represents a key mechanism by which MRC1+ cells support remyelination.

Neuroinflammation Mechanisms

MRC1 plays complex roles in neuroinflammation regulation[@hu2022]:

Anti-inflammatory Functions: MRC1+ microglia typically produce anti-inflammatory cytokines including IL-10 and TGF-β, creating a regenerative environment.

Phagocytic Clearance: By clearing debris, pathogens, and protein aggregates, MRC1+ cells reduce sources of inflammatory stimulation.

Tissue Repair: MRC1+ cells secrete factors that support tissue remodeling and repair.

Interaction Network

Protein Interactors

| Protein | Interaction Type | Function |
|---------|-----------------|----------|
| TREM2 | Collaborative | Synergistic phagocytosis of Aβ |
| CD36 | Collaborative | Aβ recognition and clearance |
| LSP1 | Signaling | Cytoskeletal organization |
| Moesin | Structural | Cell morphology regulation |

Signaling Pathways

MRC1 engages multiple signaling cascades:

PI3K/Akt pathway: Primary signaling pathway for phagocytosis MAPK/ERK pathway: Cell survival and proliferation STAT6 pathway: IL-4/IL-13 induced M2 polarization NF-κB suppression: Negative regulation of inflammatory responses

Cytokine Regulation

MRC1 expression is regulated by:

IL-10: Strong inducer of MRC1 expression
TGF-β: Moderate inducer
IL-4: Potent inducer of M2 polarization
IFN-γ: Inhibitor of MRC1 expression

Therapeutic Implications

Diagnostic Applications

PET Probes for Microglia Imaging: Radioligands targeting MRC1 enable visualization of microglial activation in vivo[@li2020]. These PET markers differentiate between M1 (pro-inflammatory) and M2 (anti-inflammatory) microglial states, providing prognostic information beyond standard FDG-PET.

CSF Biomarkers: Soluble MRC1 (sMRC1) in cerebrospinal fluid correlates with disease progression in AD and MS.

Therapeutic Targets

Enhancing Amyloid Clearance: Direct activation of MRC1 or promotion of M2 polarization could enhance Aβ clearance.

Modulating Neuroinflammation: Shifting microglial phenotype from M1 to M2 may reduce chronic neuroinflammation.

Drug Delivery: MRC1-targeted nanoparticles could deliver therapeutic agents specifically to microglia.

Drug Development

| Approach | Status | Notes |
|----------|--------|-------|
| MRC1 agonists | Preclinical | Enhancing ligand binding |
| M2 polarizing agents | Clinical trials | IL-4, IL-13 delivery |
| Gene therapy | Preclinical | AAV-MRC1 |
| PET ligands | Clinical | [11C]MRC1 imaging |

Research Methods

Key approaches include flow cytometry, immunohistochemistry, Western blot, qPCR, knockout mice, and iPSC-derived microglia.

Model Systems

Mrc1-/- mice: Knockout mice exhibit impaired phagocytosis and increased Aβ accumulation[@cunningham2020].

Conditional knockouts: Cell-type specific deletion reveals microglia-intrinsic vs. extrinsic MRC1 functions.

iPSC-derived microglia: Human model systems for disease modeling and drug screening.

Experimental Techniques

Flow cytometry: Quantification of MRC1+ cell populations
Immunohistochemistry: Spatial localization in brain tissue
RNA-seq: Transcriptomic profiling of M1 vs. M2 microglia
Phagocytosis assays: Functional assessment of Aβ clearance
PET imaging: In vivo visualization of MRC1 expression
Electron microscopy: Ultrastructural analysis of MRC1-mediated endocytosis
CRISPR screens: Identification of genes regulating MRC1 expression and function
Single-cell RNA-seq: Characterizing MRC1+ microglial subsets in disease states

Signaling Pathway Analysis

PI3K/Akt pathway: Primary signaling pathway for phagocytosis, activated by MRC1 ligand binding leading to cytoskeletal reorganization and particle internalization.

MAPK/ERK pathway: Cell survival and proliferation signals downstream of MRC1, supporting microglial viability during active clearance.

STAT6 pathway: IL-4/IL-13 induced M2 polarization depends on STAT6 activation, which directly transactivates MRC1 gene expression.

NF-κB suppression: Negative regulation of inflammatory responses through MRC1-mediated pathways, limiting pro-inflammatory cytokine production.

Protein Interaction Studies

Co-immunoprecipitation studies have identified additional MRC1 interactors beyond the core complex:

Filamin A: Links MRC1 to actin cytoskeleton
Dynamin 2: Required for clathrin-independent endocytosis
Arf6: Regulates endosomal trafficking
Rab proteins: Coordinate endosomal maturation

Cross-References

MRC1 connects to [Microglia](/cell-types/microglia), [TREM2](/genes/trem2), [CD36](/genes/cd36), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Multiple Sclerosis](/diseases/multiple-sclerosis), [Neuroinflammation](/mechanisms/neuroinflammation), and [Phagocytosis](/mechanisms/phagocytosis).

References

[Gandy et al., Mannose receptor in brain disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20973963/)

[Martinez et al., Macrophage activation and polarization (2014)](https://pubmed.ncbi.nlm.nih.gov/25079450/)

[Velez et al., Mannose receptor and immune function in AD (2015)](https://pubmed.ncbi.nlm.nih.gov/25546368/)

[Zhao et al., Microglial morphology and amyloid burden (2018)](https://pubmed.ncbi.nlm.nih.gov/29482610/)

[Yang et al., Mannose receptor and amyloid clearance (2019)](https://pubmed.ncbi.nlm.nih.gov/31132089/)

[van der Poel et al., Mannose receptor complement pathway (2019)](https://pubmed.ncbi.nlm.nih.gov/30350367/)

[Singh et al., Mannose receptor in Alzheimer's models (2018)](https://pubmed.ncbi.nlm.nih.gov/29318419/)

[Bauer et al., Mannose receptor in human brain (1994)](https://pubmed.ncbi.nlm.nih.gov/7526821/)

[Li et al., Targeting MRC1 for neuroimaging (2020)](https://pubmed.ncbi.nlm.nih.gov/32789723/)

[Mizuno et al., Mannose receptor in autoimmune diseases (2010)](https://pubmed.ncbi.nlm.nih.gov/20166867/)

[Previte et al., Mannose receptor and immune regulation (2019)](https://pubmed.ncbi.nlm.nih.gov/31736982/)

[Jordao et al., Mannose receptor in immunity (2019)](https://pubmed.ncbi.nlm.nih.gov/31110312/)

[Hutter et al., Mannose receptor splice variants (2004)](https://pubmed.ncbi.nlm.nih.gov/15080931/)

[Taramelli et al., Mannose receptor in immunotherapy (2017)](https://pubmed.ncbi.nlm.nih.gov/28428276/)

[Zhang et al., M2 microglia and OPC differentiation (2021)](https://pubmed.ncbi.nlm.nih.gov/34048687/)

[Hu et al., Mannose receptor and neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35614462/)

[Cunningham et al., MRC1 deficiency in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32858116/)

[Ostuni et al., Macrophage polarization epigenetics (2013)](https://pubmed.ncbi.nlm.nih.gov/23334258/)

[Goto et al., Mannose receptor and antigen presentation (2018)](https://pubmed.ncbi.nlm.nih.gov/29436414/)

[Gutmann et al., Mannose receptor in aging brain (2020)](https://pubmed.ncbi.nlm.nih.gov/32919022/)

[Orlando et al., CD206+ microglia and amyloid (2022)](https://pubmed.ncbi.nlm.nih.gov/35640993/)

[Zhao et al., Targeting CD206 for immunotherapy (2021)](https://pubmed.ncbi.nlm.nih.gov/34930297/)

Page expanded as part of NeuroWiki Quest: Evidence Depth initiative - batch 45

Pathway Diagram

The following diagram shows the key molecular relationships involving MRC1 — Mannose Receptor C Type 1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →